Drug Discovery World

NOVEMBER 2, 2023

KS: I have been involved in the field of computational molecular biophysics for many years and more recently in protein design with my work at the European Molecular Biology Laboratory (EMBL). RA: How laborious and expensive are current antibody discovery efforts? KS: In short, incredibly so.

Antibody 83

Antibody Protein Development Drugs 83

Drug Discovery World

JANUARY 16, 2024

Biotech company ExeVir Bio has revealed new data demonstrating that its antibodies are effective in neutralising currently circulating Covid-19 Omicron variants. XVR013m is a heavy chain-only antibody targeting a unique membrane-proximal epitope in the S2 subunit of the spike protein. XVR012 demonstrates an IC50 range of 0.8

Antibody 104

Antibody Protein Vaccination Vaccine 104

Drug Discovery World

JANUARY 26, 2024

Researchers from Tokyo University of Science (TUS) have found a simple, low-cost way to optimise the production of monoclonal antibodies (mAbs) and reduce manufacturing costs. During ER stress response, protein folding ceases, resulting in the arrest of the normal function of cells.

Antibody 102

Antibody Research Protein Production 102

Drug Discovery World

JANUARY 30, 2024

A UK-based start-up is developing technology to build a pharmaceuticals factory in space that will make antibody treatments more accessible and easier to administer. BioOrbit are aiming to build the first pharmaceuticals factory in microgravity and are currently developing a platform for large-scale crystallisation of protein drugs.

Antibody 98

Antibody Protein Manufacturing Drugs 98

Scienmag

DECEMBER 16, 2021

MADISON — Small, unique antibody-like proteins known as VNARs — derived from the immune systems of sharks — can prevent the virus that causes COVID-19, its variants, and related coronaviruses from infecting human cells, according to a new study published Dec.

Protein 87

Protein Antibody Medicine 87

Pharmaceutical Technology

MAY 8, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Anti-influenza antibody compositions. However, not all innovations are equal and nor do they follow a constant upward trend.

Antibody 246

Antibody Vaccination Vaccine Dermatology 246

Drug Discovery World

MARCH 4, 2024

In an early phase clinical trial, a combination of antibody-based medications targeting the immune system generated promising safety data and anti-tumour activity in individuals with advanced cancer. The post Antibody therapy shows anti-tumour activity in advanced cancer appeared first on Drug Discovery World (DDW).

Antibody 115

Antibody Immune Response Trials Clinical Trials 115

Pharmaceutical Technology

MARCH 9, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology in Pharmaceuticals: Tumour antibody serum compositions. The production of antibodies in response to proteins expressed during cancer development serves as a biomarker.

Antibody 147

Antibody Production Protein Regulation 147

BioPharma Reporter

NOVEMBER 9, 2023

The proof-of-concept trial, dubbed IRIS-RA, is the first to investigate a treatment for rheumatoid arthritis that blocks a protein called neonatal Fc receptor (FcRn).

Antibody 105

Antibody Drugs Protein Trials 105

Drug Discovery World

MARCH 12, 2024

Here, experts weigh in on the future of monoclonal antibodies (mAbs). Amanda Halford, President Bioprocess, Cytiva “In 2024, the emphasis will remain on novel mAbs, specifically antibody drug conjugates. Secondary, there is a growing interest in replacing the cytotoxic head with non-toxic alternatives, like protein degraders.

Antibody 81

Antibody FDA Approval Drugs Development 81

Bio Pharma Dive

FEBRUARY 15, 2024

Armed with $94 million in funding, the biotech is marrying antibody-drug conjugates with protein degraders to create a new kind of cancer medicine.

Protein 189

Protein Antibody Medicine Drugs 189

Medical Xpress

FEBRUARY 22, 2023

Medicines that are based on mRNAs and proteins—particularly vaccines and antibodies—are time-intensive and costly to make. The challenge is in producing the necessary mRNAs and proteins in large enough amounts at low cost.

Protein 75

Protein Medicine Production Antibody 75

Medical Xpress

MAY 16, 2023

Antibodies are proteins produced by our immune system, that protect us from foreign antigens that enter our body. Generally, an antibody only binds to one antigen via an epitope. These bind to antigens through epitopes, i.e., binding sites on antigens, to subsequently eliminate them.

Antibody 98

Antibody Protein 98

Scienmag

NOVEMBER 17, 2021

Chemical topology is a unique dimension for protein engineering. Over the past few years, the discovery of topological nontrivial proteins in nature has already revealed their many potential functional benefits, such as enhanced thermal/mechanical/chemical stability.

Protein 80

Protein Antibody Engineer Development 80

Bio Pharma Dive

AUGUST 14, 2023

Elrexfio is the third bispecific antibody cleared to treat the blood cancer, and will compete with other therapies that target the “BCMA” protein on myeloma cells.

FDA Approval 246

FDA Approval Protein Antibody Drugs 246

Bio Pharma Dive

OCTOBER 20, 2022

The deal gives AbbVie an experimental medicine for idiopathic pulmonary fibrosis, as well as a platform for designing antibody drugs that can target proteins known as GPCRs.

Protein 326

Protein Antibody Medicine Drugs 326

STAT News

DECEMBER 10, 2022

NEW ORLEANS — Researchers had hoped in recent years that a protein called GPRC5D might offer a new way to get the immune system to hunt down and destroy multiple myeloma cells. Now, the results of a Phase 2 study on a bispecific antibody targeting this protein offers confirmation.

Antibody 132

Antibody Protein Trials Research 132

Medical Xpress

APRIL 25, 2023

In a new investigation, scientists from La Jolla Institute for Immunology (LJI) have shown how antibodies, collected from this clinical study volunteer, bind to the SARS-CoV-2 "Spike" protein to neutralize the virus. An anonymous San Diego resident has become a fascinating example of how the human immune system fights SARS-CoV-2.

Antibody 98

Antibody Protein Scientist 98

Scienmag

OCTOBER 23, 2020

Oncotarget recently published a novel format for recombinant antibody-interleukin-2 fusion proteins exhibits superior tumor-targeting properties in vivo which reported that here, the authors describe four novel formats for the L19-IL2 fusion Credit: Correspondence to – Dario Neri – dario.neri@pharma.ethz.ch

Recombinant Antibody 53

Recombinant Antibody Protein Antibody In-Vivo 53

Scienmag

DECEMBER 27, 2021

An international team of scientists have identified antibodies that neutralize omicron and other SARS-CoV-2 variants. These antibodies target areas of the virus spike protein that remain essentially unchanged as the viruses mutate.

Antibody 73

Antibody Scientist Protein Vaccination 73

Bio Pharma Dive

OCTOBER 26, 2022

The treatment, which will be sold as Tecvayli, is the first bispecific antibody cleared for the disease. It joins a group of medicines on market that target a protein called BCMA.

Protein 290

Protein Antibody Medicine Drugs 290

BioTech 365

OCTOBER 11, 2021

FC (Fragment Crystallizable) Protein and Glyco-engineered Antibodies Market, 2030 – ResearchAndMarkets.com FC (Fragment Crystallizable) Protein and Glyco-engineered Antibodies Market, 2030 – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “Fc Protein and Glyco-engineered Antibodies Market: Focus on Type of Fc Engineering (..)

Engineer 40

Engineer Protein Antibody Marketing 40

Drug Discovery World

JULY 24, 2023

The Defense Advanced Research Projects Agency (DARPA) has announced that Ginkgo Bioworks, which is building a platform for cell programming and biosecurity, has been awarded a four-year contract worth up to $18 million to reimagine how to manufacture complex therapeutic proteins.

Protein 52

Protein Manufacturing Gene Sequencing Production 52

Scienmag

JULY 23, 2021

Antibodies capable of neutralizing multiple SARS-CoV-2 strains can inform strategies for broadly protective COVID-19 booster vaccines As the SARS-CoV-2 virus that causes COVID-19 continues to evolve, immunologists and infectious diseases experts are eager to know whether new variants are resistant to the human antibodies that recognized initial versions (..)

Antibody 75

Antibody Protein Vaccination Vaccine 75

Scienmag

JANUARY 25, 2022

An international team of scientists has determined the precise structural changes in the spike protein of the omicron variant. Their observations explain how the virus is able to evade antibodies against previous variants and still remain highly infectious.

Protein 79

Protein Scientist Antibody 79

Bio Pharma Dive

SEPTEMBER 7, 2023

The alliance, which aims to combine Seagen’s antibody expertise with Nurix’s targeted protein degradation research, comes as the larger biotech awaits its acquisition by Pfizer to close.

Protein 177

Protein Antibody Drugs Research 177

BioTech 365

JANUARY 12, 2021

OXGENE Introduces SLIM Platform for Discovery of Antibodies Against Membrane Proteins OXGENE Introduces SLIM Platform for Discovery of Antibodies Against Membrane Proteins Novel self-labelling mammalian display method for identifying antibodies against membrane proteins in their native configuration Paper published in … Continue reading → (..)

Protein 52

Protein Antibody 52

Bio Pharma Dive

MAY 18, 2021

The pharma acquired rights to an experimental antibody medicine that blocks a protein, called TIGIT, that's become a focus for several cancer drugmakers.

Protein 337

Protein Antibody Medicine Drugs 337

Drug Discovery World

JANUARY 10, 2023

For over 50 years, Bethyl Laboratories (now a Fortis Life Sciences brand) has been dedicated to improving lives by supporting scientific discovery through qualified antibody products and custom services. All of our antibodies are highly validated using six pillars of validation, meaning that our antibodies do what we say they’ll do.

Antibody 52

Antibody Protein Reagent Scientist 52

Drug Discovery World

DECEMBER 20, 2022

A project creating a new class of therapeutic proteins to modulate cell signalling has been accepted into the BioInnovation Institute (BII) Bio Studio programme. De novo protein design is an exciting area and one that fits perfectly with our strategy to accelerate the commercialisation of state-of-the-art technology.” .

Protein 52

Protein Life Science Antibody Business Development 52

Pharmaceutical Technology

JANUARY 16, 2024

Disco has built a protein mapping platform for cancer cell surfaces, to unlock targets for the antibody-based therapy market.

Protein 130

Protein Antibody Marketing 130

Drug Discovery World

JUNE 1, 2023

Antibody-drug conjugates (ADCs) are biopharmaceutical products in which a monoclonal antibody (mAB) is linked to a small molecule drug with a stable linker 1. To overcome this challenge, Synaffix has developed an innovative technology platform that can rapidly and efficiently convert any antibody into an ADC.

Antibody 98

Antibody Marketing Drugs Licensing 98

Pharmaceutical Technology

JUNE 20, 2023

Developed using pharmaceutical company GSK’s pandemic adjuvant, the vaccine targets the receptor-binding domain of the SARS-CoV-2 spike protein. The vaccine is based on recombinant protein vaccine technology and is suitable for storage between 2°C and 8°C.

Vaccination 363

Vaccination Vaccine Protein Clinical Trials 363

Scienmag

APRIL 22, 2021

SARS-CoV-2 can recruit a haem metabolite to evade antibody immunity Researchers have identified another potential target for neutralizing antibodies on the SARS-CoV-2 Spike protein that is masked by metabolites in the blood.

Antibody 46

Antibody Protein Scientist Research 46

Pharmaceutical Technology

DECEMBER 20, 2023

Gilead Sciences has signed a licence agreement for Compugen’s pre-clinical antibody programme against IL-18 binding protein for $848m.

Protein 130

Protein Antibody 130

Bio Pharma Dive

JUNE 16, 2023

The approval of Columvi adds another “bispecific antibody” to the market, highlighting the fast research progress for drugs that target two proteins rather than one.

FDA Approval 177

FDA Approval Drugs Protein Antibody 177

Bio Pharma Dive

JUNE 5, 2023

Results from a “basket” trial of the antibody-drug conjugate show it shrank tumors across a half dozen cancers, suggesting a broader role to targeting the protein HER2.

Drugs 183

Drugs Protein Antibody Trials 183